May 12, 2021Open Access

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma

Key Points

Key points are not available for this paper at this time.

Abstract

Patients with severe, uncontrolled asthma who received tezepelumab had fewer exacerbations and better lung function, asthma control, and health-related quality of life than those who received placebo. (Funded by AstraZeneca and Amgen; NAVIGATOR ClinicalTrials.gov number, NCT03347279.).

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Menzies‐Gow et al. (Wed,) studied this question.

synapsesocial.com/papers/69d8a951d2f7327e70ae3d9e https://doi.org/https://doi.org/10.1056/nejmoa2034975

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Tezepelumab in Adults with Uncontrolled Asthma2017 · 938 citations
2The production of IgE2001 · 2 citations
3Tezepelumab Treatment Effect on Annualized Rate of Exacerbations by Baseline Biomarkers in Uncontrolled Severe Asthma Patients: Phase 2b PATHWAY Study2019 · 19 citations
4A025 TEZEPELUMAB EFFICACY IN SEVERE ASTHMA BY SPECIFIC ALLERGEN SENSITIVITY: RESULTS FROM THE PATHWAY STUDY2020 · 1 citations
5Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies2016 · 553 citations

Bookmark

View Full Paper